Healthcare / Medical DevicesNasdaqGS
$1.58
+0.09 (+6.04%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-212.2M · quality 43.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
19/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$491M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10214.5%
↓Gross Margin
28.6%
↓Debt/Equity
131.32
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+55.6%
FCF CAGR
—
FCF margin
-74.3%
FCF / Net income
0.22x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $160.0M · net income $-546.4M · FCF $-118.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $160.0M | $160.0M | $154.0M | $200.5M | $128.3M | — | — | — | $78.6M | $93.5M | $90.7M | $92.8M | $60.6M | $28.2M | $26.0M | $33.9M | $1.7M | $135000.00 |
| Net Income | $-546.4M | $-546.4M | $-309.9M | $-306.7M | $-314.2M | $-181.2M | $29.4M | $-84.1M | $-102.6M | $-92.2M | $-74.4M | $-31.7M | $-66.2M | $-79.3M | $-94.5M | $-109.4M | $-140.2M | $-87.7M |
| EBITDA | $-152.7M | $-152.7M | $-242.8M | $-277.3M | $-282.2M | — | — | — | $-93.8M | $-81.3M | $-67.4M | $-25.5M | $-58.6M | $-71.9M | $-87.7M | $-104.0M | — | — |
| EPS | -1.82 | -1.82 | -1.58 | -1.21 | -1.40 | -0.89 | 0.17 | -0.55 | -0.76 | — | — | — | — | — | — | — | — | — |
| Gross Margin | 28.6% | 28.6% | 24.2% | 26.3% | 38.2% | — | — | — | 31.9% | 37.1% | 48.7% | 57.6% | 38.6% | 22.8% | 3.6% | 38.5% | 100.0% | 100.0% |
| Operating Margin | -348.5% | -348.5% | -188.7% | -154.8% | -237.6% | — | — | — | -128.4% | -96.1% | -78.5% | -31.4% | -103.7% | -275.2% | -363.1% | -324.1% | — | — |
| Net Margin | -341.5% | -341.5% | -201.2% | -153.0% | -244.9% | — | — | — | -130.4% | -98.6% | -82.0% | -34.2% | -109.2% | -281.4% | -363.6% | -323.0% | -8373.1% | -64965.2% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 131.32 | 131.32 | 1.33 | 1.33 | 1.68 | 1.13 | — | 0.29 | 0.13 | 0.16 | 0.19 | — | 0.26 | 0.19 | 0.02 | 0.01 | 0.01 | — |
| Current Ratio | 5.65 | 5.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-118.9M | $-118.9M | $-212.2M | $-268.0M | $-280.1M | $-117.1M | $18.5M | $-81.1M | $-68.3M | $-78.0M | $-76.1M | — | — | $-30.7M | $-78.5M | $-112.3M | $-127.3M | $-80.0M |
| Returns | ||||||||||||||||||
| ROE | -10214.5% | -10214.5% | -61.2% | -43.7% | -55.8% | -22.9% | 8.8% | -153.2% | -89.9% | -107.1% | -87.8% | -43.1% | -120.4% | -114.6% | -86.4% | -57.1% | -50.1% | 49.5% |
| Valuation | ||||||||||||||||||
| P/B | 88.60 | 88.60 | 1.13 | 3.40 | 3.35 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 3.9% | 3.9% | -23.2% | 56.3% | — | — | — | — | -15.9% | 3.0% | -2.2% | 53.1% | 115.0% | 8.5% | -23.3% | 1922.9% | 1140.0% | — |
| EPS Growth | -15.2% | -15.2% | -30.6% | 13.6% | — | -623.5% | 130.9% | 27.6% | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+64.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.58 → -1.82
Residual
+64.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.